Ignite Creation Date:
2025-12-24 @ 2:06 PM
Ignite Modification Date:
2026-01-01 @ 12:37 AM
Study NCT ID:
NCT00004895
Status:
COMPLETED
Last Update Posted:
2012-06-06
First Post:
2000-03-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Sponsor:
Northwestern University
Organization:
Study Overview
Official Title:
Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.
PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.
PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.
Detailed Description:
OBJECTIVES:
* Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer.
* Characterize the dose and tolerability of octreotide in this patient population.
OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.
Patients who respond well to study may continue octreotide for palliative effects.
PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
* Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer.
* Characterize the dose and tolerability of octreotide in this patient population.
OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.
Patients who respond well to study may continue octreotide for palliative effects.
PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: